INFANRIX DTPa-IPV+Hib susp inj (n ser pré) 0.5 ml
7680006190030
CH-619
J07CA06
08.08.
1 / 2
google
Details
- Product number
- 0061901
- CPT
- -
- Packaging group
- 1
- Unit
- Fertigspritze(n)
- Composition
- I) DTPa-IPV: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum. II) Hib: polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, lactosum, pro praeparatione. I) et II) corresp. DTPa-IPV + Hib: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, lactosum, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum.
Articles (1)
Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension
Pulver
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
I
|
- | Substance | Wirkstoff (Principe actif) |
|
II
|
10.0 UG | Substance | Wirkstoff (Principe actif) |
|
12C
|
- | Substance | Wirkstoff (Principe actif) |
|
12C
|
- | Substance | Wirkstoff (Principe actif) |
|
II
|
- | Substance | HNIDK |
|
I
|
- | Substance | Wirkstoff (Principe actif) |
|
12C
|
25.0 UG | Substance | Wirkstoff (Principe actif) |
|
I
|
25.0 UG | Substance | Wirkstoff (Principe actif) |
|
12C
|
25.0 UG | Substance | Wirkstoff (Principe actif) |
|
I
|
25.0 UG | Substance | Wirkstoff (Principe actif) |
|
I
|
8.0 UG | Substance | Wirkstoff (Principe actif) |
|
12C
|
8.0 UG | Substance | Wirkstoff (Principe actif) |
|
12C
|
40.0 U | Substance | Wirkstoff (Principe actif) |
|
I
|
40.0 U | Substance | Wirkstoff (Principe actif) |
|
12C
|
8.0 U | Substance | Wirkstoff (Principe actif) |
|
I
|
8.0 U | Substance | Wirkstoff (Principe actif) |
|
12C
|
32.0 U | Substance | Wirkstoff (Principe actif) |
|
I
|
32.0 U | Substance | Wirkstoff (Principe actif) |
|
12C
|
10.0 UG | Substance | Wirkstoff (Principe actif) |
|
I
|
0.5 MG | Substance | HBESI |
|
12C
|
0.5 MG | Substance | HBESI |
|
I
|
- | Substance | HNIDK |
|
I
|
- | Substance | HNIDK |
|
12C
|
- | Substance | HNIDK |
|
12C
|
- | Substance | HNIDK |
|
I
|
1.8 MG | Substance | HBESI |
|
I
|
- | Substance | HNIDK |
|
12C
|
1.8 MG | Substance | HBESI |
|
I
|
- | Substance | HNIDK |
|
12C
|
- | Substance | HNIDK |
|
12C
|
- | Substance | HNIDK |
|
12C
|
- | Substance | HNIDK |
|
I
|
- | Substance | RESI |
|
I
|
- | Substance | RESI |
|
12C
|
- | Substance | RESI |
|
I
|
- | Substance | RESI |
|
I
|
- | Substance | RESI |
|
12C
|
- | Substance | RESI |
|
12C
|
- | Substance | RESI |
|
12C
|
- | Substance | RESI |
Reimbursement information
Public price
CHF 53.75
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
15/03/1999
Authorization holder
GlaxoSmithKline AG
6340 Baar
Authorization information
- Swissmedic authorization number
- 619
- Drug name
- Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension
- Galenic form
- PULSIN
- ATC Code
- J07CA06
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 29/09/1998
- Authorization expiration date
- 31/12/9999
- IT number
- 08.08.
- Domain
- Human medicine
Packaging details
- Description (FR)
- INFANRIX DTPa-IPV+Hib susp inj (n ser pré) 0.5 ml
- Description (DE)
- INFANRIX DTPa-IPV+Hib Inj Susp (n Fertspr) 0.5 ml
- Market launch
- 29/09/1998
- Narcotic (BTM)
- No
Application methods
IMU